- CEO
- Guang Xia Qin
- Full Time Employees
- 15,933
- Sector
- Retail trade
- Industry
- Drugstore chains
- Address
- Jinan China
- IPO Date
- Jul 5, 2021
- Business
- Shu Yu Civilian Pharmacy Corp., Ltd. is a China-based retail and wholesale pharmacy chain operator primarily engaged in the distribution and retail sale of pharmaceuticals, healthcare products, and medical devices. Founded in 2002 and headquartered in Jinan, Shandong Province, the company operates retail pharmacy networks, specialized Direct-to-Patient pharmacies, community medical clinics, and modern pharmaceutical logistics distribution centers across the People's Republic of China.
The company operates through integrated retail and wholesale channels, offering a comprehensive portfolio of products and services that comprises western pharmaceuticals and chemical drugs, covering cardiovascular, anti-infective, endocrine, gastrointestinal, respiratory, and oncology therapeutic categories; traditional Chinese medicines, including proprietary Chinese patent drugs, processed herbal decoction pieces, and wellness tonics; healthcare and nutritional supplements, including vitamins, dietary minerals, sports nutrition, and functional health foods; medical devices and home diagnostic equipment, such as sphygmomanometers, blood glucose meters, rehabilitation aids, surgical dressings, and personal protective gear; personal care and daily consumer goods, including cosmeceuticals, maternal and infant care supplies, oral care products, and household sanitation items; and clinical healthcare services, comprising licensed pharmacist medication counseling, chronic disease health management, prescription review, medical insurance dual-channel reimbursement fulfillment, Direct-to-Patient specialty drug distribution, and omnichannel online-to-offline on-demand delivery services.
Shu Yu Civilian Pharmacy Corp., Ltd. primarily serves retail consumers, chronic disease patients, and regional healthcare institutions, maintaining a dominant market position in Shandong Province while expanding operations across northern, northeastern, and central China, including Liaoning, Henan, Heilongjiang, Fujian, and Shaanxi provinces. In recent developments, the company has actively executed an external expansion strategy by acquiring controlling interests in multiple regional retail pharmacy chains and asset portfolios across northern and northeastern China to increase store density and market share. Additionally, the company has accelerated its digital transformation by expanding partnerships with leading third-party instant-delivery e-commerce platforms, upgrading proprietary digital membership and remote prescription inquiry systems, and expanding its network of medical insurance dual-channel designated pharmacies to capture outpatient prescription outflow from public hospitals. To support ongoing retail scale expansion, the company has continued to modernize its automated pharmaceutical logistics centers and optimize its supply chain distribution capabilities.